

New Approvals strengthen Zydus' US product basket

Ahmedabad, 29 January 2009

Zydus Cadila has received three product approvals from the USFDA in quick succession. The group has received approvals to market Lamotrigine Chewable Tablets in strengths of 2 mg, 5 mg and 25 mg, Lamotrigine Tablets - 25 mg, 50 mg, 100 mg, 150 mg, 200mg and 250 mg and Divalproex Sprinkle Capsules, 125 mg.

The branded sales in the US market of Lamotrigine Chewable Tablets was estimated at USD 101 million and that of Lamotrigine Tablets was estimated at USD 2.4 billion in 2008 as per NDC. The sales of Divalproex Sprinkle Capsules was estimated at USD 63 million in 2008 as per NDC. All three products fall under the anti-epileptic segment.

The company will market all the three drugs through its US subsidiary Zydus Pharmaceuticals (USA) Inc. The group now has 44 approvals since the commencement of filing process in FY 2003-04. So far, the group has filed 80 ANDAs and 71 DMFs.
